Physician profile
Glenn Uber
NPI 1316910128
$3,265.77
in general payments reported to CMS, 2019-2025
26 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $242 · 2021: $86.26 · 2022: $45.29 · 2023: $500 · 2024: $952 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.81 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $693.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $543.71 | 2019-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $496.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $236.52 | 2019-2024 | |
| Lilly USA, LLC | $214.96 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.19 | 2019-2024 | |
| Astellas Pharma US INC | $129.48 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $100.27 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $85.33 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $78.72 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $75.34 | 2019-2020 | |
| Edwards Lifesciences Corporation | $73.93 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $63.14 | 2020-2025 | Zoryve |
| Inspire Medical Systems, INC. | $44.67 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $40.03 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $34.66 | 2019-2020 | |
| Abbott Laboratories | $27.11 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $24.59 | 2025 | Gemtesa |
| Allergan, INC. | $23.21 | 2019 | |
| Hikma Pharmaceuticals USA | $21.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.29 | 2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $18.17 | 2019 | |
| Csl Behring | $16.30 | 2019 | |
| Boston Scientific Corporation | $14.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.09 | 2024 | Camzyos |
| Phathom Pharmaceuticals, INC. | $10.24 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Uber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.